COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes

2020112 citationsJournal Articlebronze Open Access

Authors

Rebecca H. Haberman · New York University Langone Orthopedic Hospital

Rochelle Castillo · New York University Langone Orthopedic Hospital

Alan Chen · New York University Langone Orthopedic Hospital

Di Yan · New York University Langone Orthopedic Hospital

Deborah Ramirez · New York University Langone Orthopedic Hospital

Vaish Sekar · New York University

Robert L. Lesser

Abstract

Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.

Topics & Keywords

COVID-19 Clinical Research Studies Rheumatoid Arthritis Research and Therapies Long-Term Effects of COVID-19

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis & Rheumatology

Volume 72, Issue 12, pp. 1981-1989

DOI: 10.1002/art.41456

Field-Weighted Citation Impact: 2.64